[1] |
Mitoma H, Adhikari K, Aeschlimann D, et al. Consensus paper: Neuroimmune mechanisms of cerebellar ataxias[J]. Cerebellum, 2016, 15(2): 213-232.
doi: 10.1007/s12311-015-0664-x
pmid: 25823827
|
[2] |
Muñoz-Lopetegi A, Boukhrissi S, et al. Neurologic syndromes related to anti-GAD65: Clinical and serologic response to treatment[J]. Neurol Neuroimmunol Neuroinflamm, 2020, 7(3):e696.
|
[3] |
Bai L, Ren H, Liang M, et al. Neurological disorders associated with glutamic acid decarboxylase 65 antibodies: Clinical spectrum and prognosis of a cohort from China[J]. Front Neurol, 2022, 13:990553.
|
[4] |
刘峥, 董会卿, 邱占东, 等. GAD-65抗体相关性小脑性共济失调病例报道及文献回顾[J]. 脑与神经疾病杂志, 2017, 25(7):397-401.
|
[5] |
刘静, 樊春秋, 刘爱华, 等. GAD65抗体相关性小脑共济失调临床及眼震电图一例[J]. 脑与神经疾病杂志, 2020, 28(9):574-577.
|
[6] |
朱丽平, 刘磊, 彭静婷, 等. GAD65抗体相关性小脑性共济失调一例报道及文献复习[J]. 中国神经免疫学和神经病学杂志, 2020, 27(01):46-50.
|
[7] |
杨桦, 赵敏, 任雪飞, 等. 抗谷氨酸脱羧酶65抗体相关性小脑性共济失调1例报道[J]. 国际神经病学神经外科学杂志, 2020, 47(1):85-86.
|
[8] |
高颖, 黄瑶, 侯彦波, 等. 抗谷氨酸脱羧酶65抗体阳性相关中枢神经系统病变临床特点分析[J]. 中风与神经疾病杂志, 2022, 39(7): 647-649.
|
[9] |
任若琳, 张哲, 王亚杰, 等. 抗GAD-65抗体相关小脑性共济失调合并僵人综合征1例[J]. 浙江医学, 2022, 44(7): 758-759+766.
|
[10] |
刘芳芳, 黄培生, 陈金梅, 等. GAD65抗体相关性小脑性共济失调(附1例报告及文献复习)[J]. 中国临床神经科学, 2023, 31(01): 75-80.
|
[11] |
Honnorat J, Saiz A, Giometto B, et al. Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: Study of 14 patients[J]. Arch Neurol, 2001, 58(2): 225-230.
|
[12] |
Saiz A, Blanco Y, Sabater L, et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: Diagnostic clues for this association[J]. Brain, 2008, 131(Pt 10): 2553-2563.
doi: 10.1093/brain/awn183
pmid: 18687732
|
[13] |
Ariño H, Gresa-Arribas N, Blanco Y, et al. Cerebellar ataxia and glutamic acid decarboxylase antibodies: Immunologic profile and long-term effect of immunotherapy[J]. JAMA Neurol, 2014, 71(8): 1009-1016.
doi: 10.1001/jamaneurol.2014.1011
pmid: 24934144
|
[14] |
Budhram A, Sechi E, Flanagan EP, et al. Clinical spectrum of high-titre GAD65 antibodies[J]. J Neurol Neurosurg Psychiatry, 2021, 92(6):645-654.
|
[15] |
Martin DL, Rimvall K. Regulation of gamma-aminobutyric acid synthesis in the brain[J]. J Neurochem, 1993, 60(2): 395-407.
pmid: 8419527
|
[16] |
Kajita Y, Mushiake H. Heterogeneous GAD65 Expression in subtypes of GABAergic neurons across layers of the cerebral cortex and hippocampus[J]. Front Behav Neurosci, 2021, 15:750869.
|
[17] |
McKeon A, Tracy JA. GAD65 neurological autoimmunity[J]. Muscle Nerve, 2017, 56(1):15-27.
doi: 10.1002/mus.25565
pmid: 28063151
|
[18] |
Jazebi N, Rodrigo S, Gogia B, et al. Anti-glutamic acid decarboxylase (GAD) positive cerebellar Ataxia with transitioning to progressive encephalomyelitis with rigidity and myoclonus (PERM), responsive to immunotherapy: A case report and review of literature[J]. J Neuroimmunol, 2019, 332:135-137.
doi: S0165-5728(18)30577-0
pmid: 31015081
|
[19] |
Olberg HK, Eide GE, Vedeler CA. Can serum GAD65 antibody levels predict neurological disease or cancer?[J]. J Neuroimmunol, 2019, 336:577025.
|
[20] |
Li TR, Zhang YD, Wang Q, et al. Intravenous methylprednisolone or immunoglobulin for anti-glutamic acid decarboxylase 65 antibody autoimmune encephalitis: Which is better?[J]. BMC Neurosci, 2020, 21(1):13.
|
[21] |
Mitoma H, Manto M, Hampe CS. Immune-mediated cerebellar ataxias: Practical Guidelines and therapeutic challenges[J]. Curr Neuropharmacol, 2019, 17(1):33-58.
doi: 10.2174/1570159X16666180917105033
pmid: 30221603
|